Optimal treatment for Siewert type II and III adenocarcinoma of the esophagogastric junction: A retrospective cohort study with long-term follow-up

Table 1 Baseline characteristics of patients and therapeutic approaches (n = 83) n (%)

	Type II (n = 62)	Type III (n = 21)	P value
Age (yr)			0.72
Median (range)	68.5 (33-87)	69 (54-80)
Sex			0.78
Male	49 (79)	16 (76)
Female	13 (21)	5 (24)
Tumor size (mm)	50 (10-168)	70 (12-120)	0.016
Esophageal invasion (mm)	9 (0-85)	5 (0-15)	0.024
Total number of examined lymph nodes	36.5 (5-96)	51 (22-80)	0.016
Approach
Right thoracic	8 (13)	0 (0)
Left thoracic	8 (13)	1 (5)
Transhiatal	46 (74)	20 (95)
Resection method
Subtotal esophagectomy	8 (13)	0 (0)
Total gastrectomy with distal esophagectomy	37 (60)	21 (100)
Proximal gastrectomy with distal esophagectomy	17 (27)	0 (0)
Adjuvant chemotherapy			0.24
Yes	19 (31)	9 (43)
No	43 (69)	12 (57)

Type II: Siewert type II adenocarcinoma of the esophagogastric junction; Type III: Siewert type III adenocarcinoma of the esophagogastric junction.